Multi-Omics Inflammatory Phenotype for ABPA Recurrence Risk Prediction

Recruiting now

Conditions studied: Allergic Bronchopulmonary Aspergillosis (ABPA), Machine Learning, Multi-omics, Multicenter Study, Relapse

In brief

To develop and externally validate a machine learning model for predicting the 1-year risk of relapse in patients with stable ABPA, and to further evaluate its value in risk stratification and clinical decision-making.

Key facts

Study ID

NCT07611838

Run by

Qianfoshan Hospital

People needed

300

Starts

2021-01-01

Expected to finish

2028-12-31

Last updated by the study team

2026-06-01

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Female and Male patients aged 18-80 years
• diagnosis of Allergic Bronchopulmonary Aspergillosis ABPA accroding to the 2024 ISHAM Working Group Diagnostic Criteria

You may not qualify if…

• Patients with malignant tumors or severe organ dysfunction (e.g., cardiac, cerebral, renal, etc.)
• Patients with severe comorbidities, including active pulmonary tuberculosis, lung cancer, chronic heart failure (NYHA class Ⅳ), chronic kidney disease (CKD stage 5), decompensated cirrhosis, etc.
• Patients with immunosuppressive status, such as HIV infection, long-term use of oral corticosteroids or immunosuppressive agents.
• Pregnant or lactating women.
• Patients with missing key data or incomplete medical records.

Where it is running

• Department of Respiratory, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, #16766, Jingshi Road, Jinan City, Shandong Province, China, Jinan, Shandong 250014 — Jinan, Shandong, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.